J Korean Med Assoc.  2019 Jan;62(1):11-17. 10.5124/jkma.2019.62.1.11.

Diagnosis and treatment of latent tuberculosis infection

• Min J
• Kim JS

• KMID: 2431990
• DOI: http://doi.org/10.5124/jkma.2019.62.1.11

Abstract

In order to eliminate tuberculosis worldwide by 2050, effective management of latent tuberculosis infection is essential, and policy-makers have begun to recognize the importance of scaling up preventive therapy. The current guideline recommends targeted latent tuberculosis infection testing that identifies high-risk groups based on risk stratification for progression from latent infection to active disease. Both the tuberculin skin test and interferon-gamma releasing assay have a similar diagnostic efficacy for predicting progression to active tuberculosis. The Korean guideline recommends 9-month isoniazid monotherapy as the standard treatment; however, more evidence supports that short course rifampicin-based regimen is both more effective and tolerable than isoniazid monotherapy.

Keyword

Latent tuberculosis; Antituberculosis agent; Interferon-gamma release assay; Tuberculin skin test

MeSH Terms

Diagnosis*
Interferon-gamma
Interferon-gamma Release Tests
Isoniazid
Latent Tuberculosis*
Skin Tests
Tuberculin
Tuberculosis
Interferon-gamma
Isoniazid
Tuberculin